Malaria Diagnostics Market Overview
The Malaria Diagnostics Market is witnessing steady growth as malaria-endemic countries strengthen disease surveillance, expand community-level testing, and adopt more sensitive diagnostic technologies. Sustained funding for malaria control, increasing emphasis on elimination programs, and advances in molecular diagnostics, rapid testing, and AI-assisted microscopy are supporting demand for faster and more accurate detection solutions.
According to the Market Research Future report updated August 24, 2026, the Malaria Diagnostics Market was valued at USD 0.93 Billion in 2025 and is projected to grow from USD 0.98 Billion in 2026 to USD 1.62 Billion by 2035, registering a CAGR of 5.72% during the forecast period from 2026 to 2035. Middle East & Africa dominated the market with approximately 76.2% of global revenue in 2025, driven by the high malaria burden and large-scale diagnostic procurement, while Asia-Pacific is projected to be the fastest-growing region at a 7.54% CAGR. Rapid Diagnostic Tests accounted for approximately 56.5% of market revenue in 2025, while Molecular Diagnostics are projected to register the fastest technology growth at a 6.28% CAGR. Clinics represented the largest end-user segment with approximately 55.8% share, while Diagnostic Centres are forecast to grow at a 6.65% CAGR.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
Key players driving innovation and competitiveness in the Malaria Diagnostics Market include:
Abbott Laboratories
bioMérieux SA
Access Bio Inc.
Sysmex Corporation
Bio-Rad Laboratories
Meridian Bioscience
Premier Medical Corporation
Hologic Inc.
Ortho Clinical Diagnostics
Siemens Healthineers
The Malaria Diagnostics Market is being transformed by the shift from conventional microscopy toward rapid, molecular, and AI-assisted diagnostic technologies. Rapid Diagnostic Tests remain essential for mass community-level screening because of their affordability, portability, and minimal infrastructure requirements, while molecular platforms are gaining importance in elimination-phase settings where highly sensitive detection of low-density and asymptomatic infections is critical. Dual-antigen testing is also gaining traction in regions affected by HRP2 gene deletions, strengthening the need for improved diagnostic accuracy.
The Malaria Diagnostics Market can be segmented by technology, end user, product type, and application. By technology, Rapid Diagnostic Tests hold the largest share at approximately 56.5%, while Molecular Diagnostics are the fastest-growing technology segment with a 6.28% CAGR. By end user, Clinics dominate with approximately 55.8% of revenue, while Diagnostic Centres are projected to expand at a 6.65% CAGR. By product type, Test Kits represent a major category alongside Reagents and Instruments. By application, the market includes Clinical Diagnosis, Epidemiological Studies, and Drug Efficacy Studies, with clinical diagnosis representing the core demand base. The market also covers Microscopy, Serology Tests, and Loop-Mediated Isothermal Amplification technologies.
Significant opportunities are emerging from CRISPR-based point-of-care diagnostics, AI-enabled microscopy, digital disease surveillance, private-sector pharmacy testing, multiplexed fever panels, and localized diagnostic manufacturing. As countries transition from malaria control toward elimination, demand is shifting toward highly sensitive molecular platforms capable of identifying low-level infections. Growing investment in diagnostic infrastructure across Asia-Pacific and Africa is creating additional opportunities for manufacturers to expand local production, improve last-mile access, and integrate connectivity into diagnostic platforms.
Recent Developments and Market Trends:
The continued expansion of Rapid Diagnostic Test procurement is strengthening decentralized malaria screening, particularly across community health facilities in high-burden African markets.
Molecular diagnostics are gaining momentum as elimination programs increasingly require sensitive detection of low-density and asymptomatic malaria infections that conventional rapid tests may miss.
Dual-antigen rapid tests are becoming increasingly important in areas affected by HRP2 gene deletions, encouraging national programs to update diagnostic procurement specifications.
AI-assisted digital microscopy and automated image-recognition systems are emerging as promising technologies for improving diagnostic accuracy, reducing turnaround times, and minimizing inter-reader variability.
Multiplexed fever panels are creating new opportunities by combining malaria detection with tests for other causes of febrile illness such as dengue, chikungunya, and typhoid.
Reasons to Buy the Report:
Gain comprehensive insights into the global Malaria Diagnostics Market size, growth rate, and forecast through 2035.
Understand the major technology, end-user, product-type, and application segments shaping market demand.
Evaluate regional opportunities across North America, Europe, South America, Asia-Pacific, and the Middle East & Africa.
Identify leading companies, competitive strategies, diagnostic innovations, procurement trends, and emerging market opportunities.
Use strategic market intelligence to assess investment opportunities, product development, regional expansion, and future growth prospects.
Future Outlook:
The Malaria Diagnostics Market is expected to maintain steady growth through 2035 as endemic countries intensify elimination programs, expand decentralized testing, and adopt more sensitive diagnostic technologies. Rapid Diagnostic Tests will remain the dominant technology because of their affordability, ease of deployment, and suitability for community-level screening, while Molecular Diagnostics are projected to experience the fastest growth as elimination-phase programs increasingly require detection of low-density and asymptomatic infections. Clinics will continue to represent the largest end-user segment because of their central role in primary and outpatient malaria testing, while Diagnostic Centres are expected to expand rapidly as referral networks mature and molecular confirmation becomes more widely adopted. Test Kits will remain a major product category due to their high-volume use in endemic regions, while Reagents and Instruments will benefit from the expansion of laboratory-based and molecular testing. Middle East & Africa is expected to maintain overwhelming regional leadership, supported by the high malaria burden, large-scale procurement programs, and sustained investments in disease control, while Asia-Pacific is projected to remain the fastest-growing region at a 7.54% CAGR as India and Southeast Asia intensify elimination and surveillance activities. Continued development of CRISPR-based assays, AI-assisted microscopy, digital surveillance platforms, multiplexed fever panels, dual-antigen RDTs, and localized manufacturing is expected to support the market’s progression toward USD 1.62 Billion by 2035 at a CAGR of 5.72%.
➤➤Explore Our Latest Related Reports:
